XML 95 R28.htm IDEA: XBRL DOCUMENT v3.19.3
Segments Segments
 9 Months Ended
Sep. 30, 2019
Segment Reporting [Abstract]  
Segments Segments
Through March 31, 2019, the Company was a single operating segment. In April 2019, the Company initiated efforts to better deploy resources, realize inherent synergies, and position the Company for growth with a core focus on healthcare and initiated plans to achieve this through various corporate activities, including partnering, potential asset sales, and operating cost reductions. Thereafter, the Company's CODM assessed the operating performance of and allocated resources for several operating segments using Segment Adjusted EBITDA. Management believes this financial metric is a key indicator of operating results since it excludes noncash revenues and expenses that are not reflective of the underlying business performance of an individual enterprise. The Company defines Segment Adjusted EBITDA as net loss before (i) interest expense, (ii) income tax expense or benefit, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) loss on impairment of goodwill and other long-lived assets, (vi) equity in net loss of affiliates, and (vii) recognition of previously deferred revenue associated with upfront and milestone payments as well as cash outflows from capital expenditures and investments in affiliates.
Because the Company uses Segment Adjusted EBITDA as its primary measure of segment performance, it has included this measure in its discussion of segment operating results. The Company has also disclosed revenues from external customers and intersegment revenues for each reportable segment. Corporate expenses are not allocated to the segments and are managed at a consolidated level. The CODM does not use total assets by segment to evaluate segment performance or allocate resources, and accordingly, these amounts are not required to be disclosed. The Company's CODM now regularly reviews disaggregated financial information for each of the Company's operating segments. The Company's segment presentation has been recast to retrospectively reflect the change from one reportable segment to the newly identified reportable segments.
For the three and nine months ended September 30, 2019, the Company's reportable segments are (i) Precigen, (ii) MBP, (iii) the Fine Chemicals division, (iv) Okanagan, and (v) Trans Ova. These identified reportable segments met the quantitative thresholds for the nine months ended September 30, 2019, to be reported separately. See Note 1 for a description of Precigen, MBP, Okanagan, and Trans Ova. The Company's Fine Chemicals division is an operating division within Intrexon which is focused primarily on microbial production of therapeutic compounds. The All Other category as reported below reflects Intrexon's other operating segments that do not meet the quantitative thresholds to report separately.
Information by reportable segment was as follows:
 
Three Months Ended September 30, 2019
 
Precigen
 
MBP
 
Fine Chemicals
 
Okanagan
 
Trans Ova
 
All Other
 
Total
Revenues from external customers
$
444

 
$
1,117

 
$
2,177

 
$
6

 
$
13,981

 
$
5,318

 
$
23,043

Intersegment revenues
2,313

 
—

 
1,225

 
—

 
257

 
78

 
3,873

Total revenues
$
2,757

 
$
1,117

 
$
3,402

 
$
6

 
$
14,238

 
$
5,396

 
$
26,916

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Segment Adjusted EBITDA
$
(5,953
)
 
$
(9,024
)
 
$
144

 
$
(4,323
)
 
$
(5,560
)
 
$
(8,526
)
 
$
(33,242
)
 
Three Months Ended September 30, 2018
 
Precigen
 
MBP
 
Fine Chemicals
 
Okanagan
 
Trans Ova
 
All Other
 
Total
Revenues from external customers
$
6,822

 
$
2,083

 
$
1,103

 
$
10

 
$
15,634

 
$
6,771

 
$
32,423

Intersegment revenues
200

 
2

 
1,160

 
—

 
136

 
120

 
1,618

Total revenues
$
7,022

 
$
2,085

 
$
2,263

 
$
10

 
$
15,770

 
$
6,891

 
$
34,041

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Segment Adjusted EBITDA
$
(7,965
)
 
$
(8,192
)
 
$
(343
)
 
$
(5,158
)
 
$
(1,844
)
 
$
(9,054
)
 
$
(32,556
)
 
Nine Months Ended September 30, 2019
 
Precigen
 
MBP
 
Fine Chemicals
 
Okanagan
 
Trans Ova
 
All Other
 
Total
Revenues from external customers
$
2,174

 
$
3,813

 
$
4,167

 
$
45

 
$
53,307

 
$
18,711

 
$
82,217

Intersegment revenues
7,090

 
2

 
4,090

 
—

 
1,204

 
646

 
13,032

Total revenues
$
9,264

 
$
3,815

 
$
8,257

 
$
45

 
$
54,511

 
$
19,357

 
$
95,249

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Segment Adjusted EBITDA
$
(20,789
)
 
$
(26,238
)
 
$
(979
)
 
$
(25,367
)
 
$
(2,854
)
 
$
(26,020
)
 
$
(102,247
)
 
Nine Months Ended September 30, 2018
 
Precigen
 
MBP
 
Fine Chemicals
 
Okanagan
 
Trans Ova
 
All Other
 
Total
Revenues from external customers
$
22,285

 
$
5,030

 
$
4,211

 
$
37

 
$
59,467

 
$
26,228

 
$
117,258

Intersegment revenues
431

 
8

 
3,954

 
—

 
382

 
847

 
5,622

Total revenues
$
22,716

 
$
5,038

 
$
8,165

 
$
37

 
$
59,849

 
$
27,075

 
$
122,880

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Segment Adjusted EBITDA
$
(20,797
)
 
$
(22,059
)
 
$
(1,244
)
 
$
(16,609
)
 
$
(1,901
)
 
$
(31,088
)
 
$
(93,698
)

The table below reconciles total revenues from reportable segments to total consolidated revenues:
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2019
 
2018
 
2019
 
2018
Total revenues from reportable segments
$
21,520

 
$
27,150

 
$
75,892

 
$
95,805

Other revenues, including from other operating segments
5,396

 
6,916

 
19,504

 
27,497

Elimination of intersegment revenues
(3,873
)
 
(1,618
)
 
(13,032
)
 
(5,913
)
Total consolidated revenues
$
23,043

 
$
32,448

 
$
82,364

 
$
117,389

The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss before income taxes:
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2019
 
2018
 
2019
 
2018
Segment Adjusted EBITDA for reportable segments
$
(24,716
)
 
$
(23,502
)
 
$
(76,227
)
 
$
(62,610
)
All Other Segment Adjusted EBITDA
(8,526
)
 
(9,054
)
 
(26,020
)
 
(31,088
)
Remove cash paid for capital expenditures and investments in affiliates
8,115

 
10,373

 
34,021

 
30,422

Add recognition of previously deferred revenue associated with upfront and milestone payments
5,770

 
7,201

 
16,685

 
24,100

Other expenses:
 
 
 
 
 
 
 
Interest expense
(4,471
)
 
(3,999
)
 
(13,140
)
 
(4,240
)
Depreciation and amortization
(6,021
)
 
(8,303
)
 
(18,711
)
 
(25,184
)
Impairment loss
(626
)
 
—

 
(626
)
 
—

Reacquisition of in-process research and development
—

 
(8,721
)
 
—

 
(8,721
)
Stock-based compensation expense
(5,423
)
 
(8,132
)
 
(14,538
)
 
(28,340
)
Equity in net loss of affiliates
(1,647
)
 
(2,870
)
 
(5,034
)
 
(9,880
)
Other
35

 
—

 
35

 
—

Unallocated corporate costs
(13,544
)
 
(25,440
)
 
(43,657
)
 
(75,319
)
Eliminations
(3,092
)
 
(621
)
 
(9,104
)
 
(1,659
)
Consolidated net loss before income taxes
$
(54,146
)
 
$
(73,068
)
 
$
(156,316
)
 
$
(192,519
)

As of September 30, 2019 and December 31, 2018, the Company had $14,373 and $16,839, respectively, of long-lived assets in foreign countries. The Company recognized revenues derived in foreign countries totaling $3,325 and $2,235 for the three months ended September 30, 2019 and 2018, respectively, and $7,785 and $10,389 for the nine months ended September 30, 2019 and 2018, respectively.